NCT00092313
Completed
Phase 3
A Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Study to Evaluate the Efficacy of Rofecoxib and a Dosing Regimen of Oxycodone With Acetaminophen Over 24 Hours in Patients With Postoperative Dental Pain
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Postoperative Pain
- Sponsor
- Merck Sharp & Dohme LLC
- Enrollment
- 271
- Primary Endpoint
- Post-op dental pain over 6 hours as measured by pain intensity/relief scores, patient global assessment, and time to perceptible/meaningful pain relief.
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
The purpose of this study is to compare the safety and effectiveness of two approved drugs in the treatment of pain following dental surgery.
Detailed Description
The duration of treatment is 24 hours.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Impaction of a molar tooth requiring removal
Exclusion Criteria
- •Known allergy to the study drugs
Outcomes
Primary Outcomes
Post-op dental pain over 6 hours as measured by pain intensity/relief scores, patient global assessment, and time to perceptible/meaningful pain relief.
Secondary Outcomes
- Time to onset of analgesic effect, peak analgesic effect, and/or duration of analgesic effect over 24 hours.
Similar Trials
Completed
Phase 3
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED)Postoperative PainNCT00092300Merck Sharp & Dohme LLC450
Completed
Phase 3
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-183)Postoperative PainNCT00092326Merck Sharp & Dohme LLC269
Completed
Phase 3
A Study of Two Approved Drugs in the Treatment of Post-Bunionectomy Surgery Pain (0966-234)(COMPLETED)Postoperative PainNCT00092378Merck Sharp & Dohme LLC251
Completed
Phase 3
A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED)Postoperative PainNCT00092339Merck Sharp & Dohme LLC125
Completed
Phase 3
A Study of Two Approved Drugs in Patients With Osteoarthritis (0966-219)OsteoarthritisNCT00092352Merck Sharp & Dohme LLC395